Literature DB >> 33223203

LncRNA GAS6-AS1 facilitates the progression of breast cancer by targeting the miR-324-3p/SETD1A axis to activate the PI3K/AKT pathway.

Sijie Li1, Hongyao Jia2, Zhiru Zhang2, Di Wu3.   

Abstract

Breast cancer is one of the most prevalent cancers in women with a high incidence and mortality worldwide. A great number of studies have indicated that long non-coding RNAs (lncRNAs) play significant roles in the initiation and development of human cancers. Although it has been revealed that lncRNA GAS6-AS1 is involved in the regulation of several cancer types, the role and regulatory mechanism of GAS6-AS1 in breast cancer remain unclear. In this paper, our findings showed that GAS6-AS1 expression was significantly elevated in breast cancer tissues and cell lines, and the high level of GAS6-AS1 reflected a poor prognosis of patients with breast cancer. Moreover, GAS6-AS1 knockdown suppressed cell proliferation, migration and invasion as well as facilitated cell apoptosis. We further found that the depletion of GAS6-AS1 suppressed the PI3K/AKT signaling pathway through inhibiting the levels of pathway-related proteins. Mechanically, GAS6-AS1 acted as a competing endogenous RNA (ceRNA) to sponge miR-324-3p and upregulate SETD1A expression. Besides, GAS6-AS1 activated the PI3K/AKT pathway by targeting the miR-324-3p/SETD1A axis. Rescue assays showed that SETD1A overexpression or 740Y-P treatment reversed the inhibitory effect of silenced GAS6-AS1 on cellular progresses of breast cancer. In summary, this work first explored the molecular regulatory mechanism of GAS6-AS1 in breast cancer cells and revealed that GAS6-AS1 facilitated the malignant behaviors of breast cancer cells by the miR-324-3p/SETD1A axis to activate the PI3K/AKT pathway.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Breast cancer; GAS6-AS1; PI3K/AKT pathway; SETD1A; miR-324-3p

Mesh:

Substances:

Year:  2020        PMID: 33223203     DOI: 10.1016/j.ejcb.2020.151124

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   6.020


  7 in total

Review 1.  Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?

Authors:  Francesco Trevisani; Matteo Floris; Riccardo Vago; Roberto Minnei; Alessandra Cinque
Journal:  Cells       Date:  2022-05-17       Impact factor: 7.666

2.  microRNA-324-3p suppresses the aggressive ovarian cancer by targeting WNK2/RAS pathway.

Authors:  Fengjie Li; Zhen Liang; Yongqin Jia; Panyang Zhang; Kaijian Ling; Yanzhou Wang; Zhiqing Liang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Effects of CXCL12 isoforms in a pancreatic pre-tumour cellular model: Microarray analysis.

Authors:  Monia Cecati; Matteo Giulietti; Alessandra Righetti; Berina Sabanovic; Francesco Piva
Journal:  World J Gastroenterol       Date:  2021-04-21       Impact factor: 5.742

4.  Down-regulation of ZNF252P-AS1 alleviates ovarian cancer progression by binding miR-324-3p to downregulate LY6K.

Authors:  Li Geng; Zhongqiu Wang; Yongju Tian
Journal:  J Ovarian Res       Date:  2022-01-03       Impact factor: 4.234

5.  Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder.

Authors:  Trang Tt Truong; Chiara C Bortolasci; Briana Spolding; Bruna Panizzutti; Zoe Sj Liu; Srisaiyini Kidnapillai; Mark Richardson; Laura Gray; Craig M Smith; Olivia M Dean; Jee Hyun Kim; Michael Berk; Ken Walder
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

6.  LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis of colorectal cancer by regulating TRIM14 through miR-370-3p/miR-1296-5p and FUS.

Authors:  Qing Chen; Lin Zhou; Juan Hou; Yuxin Lin; Jie Wu; Min Tao
Journal:  J Transl Med       Date:  2022-08-12       Impact factor: 8.440

7.  lncRNA GAS6-AS1 inhibits progression and glucose metabolism reprogramming in LUAD via repressing E2F1-mediated transcription of GLUT1.

Authors:  Jing Luo; Huishan Wang; Li Wang; Gaoming Wang; Yu Yao; Kai Xie; Xiaokun Li; Lin Xu; Yi Shen; Binhui Ren
Journal:  Mol Ther Nucleic Acids       Date:  2021-05-01       Impact factor: 8.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.